NCT07018492View on ClinicalTrials.gov

Phase 1 Study of BPN14770 in Participants With Hepatic Impairment and Healthy Controls

PHASE1RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 30, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Hepatic Impairment
Interventions
DRUG

BPN14770

Administered as specified in the treatment arm.

Trial Locations (3)

32809

RECRUITING

Orlando Clinical Research Center, Orlando

33136

RECRUITING

Division of Clinical Pharmacology, University of Miami, Miami

78215

RECRUITING

Texas Liver Institute, San Antonio

Sponsors

Lead Sponsor

Shionogi
All Listed Sponsors
lead

Shionogi

INDUSTRY

NCT07018492 - Phase 1 Study of BPN14770 in Participants With Hepatic Impairment and Healthy Controls | Biotech Hunter | Biotech Hunter